Trial Profile
Study to assess real life tolerance and Lenvatinib plasma exposure after dose reduction in Thyroid Cancer Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Apr 2018
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 23 Apr 2018 New trial record
- 07 Mar 2018 Results presented at the 16th International Congress on Targeted Anticancer Therapies.